Mannan-binding lectin suppresses growth of hepatocellular carcinoma by regulating hepatic stellate cell activation via the ERK/COX-2/PGE₂ pathway

References

• Reina-Campos M, Moscat J, Diaz-Meco M. Metabolism shapes the tumor microenvironment. Curr Opin Cell Biol. 2017;48:47–53. doi:10.1016/j.ceb.2017.05.006.
   PubMed Web of Science ®Google Scholar
• Chen Q, Liu GX, Liu S, Su HY, Wang Y, Li JY, Luo C. Remodeling the tumor microenvironment with emerging nanotherapeutics. Trends Pharmacol Sci. 2018;39:59–74. doi:10.1016/j.tips.2017.10.009.
   PubMed Web of Science ®Google Scholar
• Berraondo P, Minute L, Ajona D, Corrales L, Melero I, Pio R. Innate immune mediators in cancer: between defense and resistance. Immunol Rev. 2016;274:290–306. doi:10.1111/imr.12464.
   PubMed Web of Science ®Google Scholar
• Soloski MJ. Recognition of tumor cells by the innate immune system. Curr Opin Immunol. 2001;13:154–162.
   PubMed Web of Science ®Google Scholar
• Hagerling C, Casbon AJ, Werb Z. Balancing the innate immune system in tumor development. Trends Cell Biol. 2015;25:214–220. doi:10.1016/j.tcb.2014.11.001.
   PubMed Web of Science ®Google Scholar
• Bottazzi B, Doni A, Garlanda C, Mantovani A. An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu Rev Immunol. 2010;28:157–183. doi:10.1146/annurev-immunol-030409-101305.
   PubMed Web of Science ®Google Scholar
• Bulla R, Tripodo C, Rami D, Ling GS, Agostinis C, Guarnotta C, Zorzet S, Durigutto P, Botto M, Tedesco F. C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation. Nat Commun. 2016;7:10346. doi: 10.1038/ncomms10346.
   PubMed Web of Science ®Google Scholar
• Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C, Coukos G, Lambris JD. Modulation of the antitumor immune response by complement. Nat Immunol. 2008;9:1225–1235. doi:10.1038/ni.1655.
   PubMed Web of Science ®Google Scholar
• Bonavita E, Gentile S, Rubino M, Maina V, Papait R, Kunderfranco P, Greco C, Feruglio F, Molgora M, Laface I, et al. PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer. Cell. 2015;160:700–714. doi:10.1016/j.cell.2015.01.004.
   PubMed Web of Science ®Google Scholar
• Mitsuhashi A, Goto H, Kuramoto T, Tabata S, Yukishige S, Abe S, Hanibuchi M, Kakiuchi S, Saijo A, Aono Y, et al. Surfactant protein A suppresses lung cancer progression by regulating the polarization of tumor-associated macrophages. Am J Pathol. 2013;182:1843–1853. doi:10.1016/j.ajpath.2013.01.030.
   PubMed Web of Science ®Google Scholar
• Ip WKE, Takahashi K, Ezekowitz RA, Stuart LM. Mannose-binding lectin and innate immunity. Immunol Rev. 2009;230:9–21. doi:10.1111/j.1600-065X.2009.00789.x.
   PubMed Web of Science ®Google Scholar
• Liu HZ, Zhou J, Ma D, Lu X, Ming SQ, Shan GQ, Zhang XY, Hou JL, Chen ZL, Zuo DM. Mannan binding lectin attenuates double-stranded RNA-mediated TLR3 activation and innate immunity. Febs Lett. 2014;588:866–872. doi:10.1016/j.febslet.2014.01.064.
   PubMed Web of Science ®Google Scholar
• Xu XY, Li HJ, Zhang LY, Lu X, Zuo DM, Shan GQ, Xu TY, Chen ZL. Mannan-binding lectin at supraphysiological concentrations inhibits differentiation of dendritic cells from human CD14(+) monocytes. Microbiol Immunol. 2015;59:724–734. doi:10.1111/1348-0421.12337.
   PubMed Web of Science ®Google Scholar
• Tang Y, Ma D, Ming SQ, Zhang LY, Zhou J, Shan GQ, Chen ZL, Lu X, Zuo DM. Mannan-binding lectin reduces CpG DNA-induced inflammatory cytokine production by human monocytes. Microbiol Immunol. 2015;59:231–237. doi:10.1111/1348-0421.12245.
   PubMed Web of Science ®Google Scholar
• Zhao N, Wu J, Xiong SM, Zhang LY, Lu X, Chen SL, Wu QF, Wang HL, Liu Y, Chen ZL, et al. Mannan-binding lectin, a serum collectin, suppresses T-cell proliferation via direct interaction with cell surface calreticulin and inhibition of proximal T-cell receptor signaling. Faseb J. 2017;31:2405–2417. doi:10.1096/fj.201601200RR.
   PubMed Web of Science ®Google Scholar
• Bouwman LH, Roep BO, Roos A. Mannose-binding lectin: clinical implications for infection, transplantation, and autoimmunity. Hum Immunol. 2006;67:247–256. doi:10.1016/j.humimm.2006.02.030.
   PubMed Web of Science ®Google Scholar
• Swierzko AS, Kilpatrick DC, Cedzynski M. Mannan-binding lectin in malignancy. Mol Immunol. 2013;55:16–21. doi:10.1016/j.molimm.2012.09.005.
   PubMed Web of Science ®Google Scholar
• Wang PS, Kuai J, Li H, Wang CG, Shi BJ, Zhong L. Mannose-binding lectin 2 rs11003123 polymorphism is associated with the development of hepatocellular carcinoma in patients with hepatitis B-related cirrhosis in the Chinese population. Hepatobiliary Pancreat Dis Int. 2016;15:282–288. doi:10.1016/S1499-3872(16)60050-4.
   PubMed Web of Science ®Google Scholar
• Su C, Lin Y, Cai L, Mao Q, Niu J. Association between mannose-binding lectin variants, haplotypes and risk of hepatocellular carcinoma: A case-control study. Sci Rep. 2016;6:32147. doi:10.1038/srep32147.
   PubMed Web of Science ®Google Scholar
• Gu X, Ji Q, Wang H, Jiang M, Yang J, Fang M, Wang M, Gao C. Genetic variants of mannose-binding lectin 2 gene influence progression and prognosis of patients with hepatitis B virus infection in China. Clin Res Hepatol Gastroenterol. 2016;40:614–621. doi:10.1016/j.clinre.2015.12.015.
   PubMed Web of Science ®Google Scholar
• Lin Y, Su C, Niu J, Guo Z, Cai L. Impact of mannose-binding lectin 2 polymorphism on the risk of hepatocellular carcinoma: a case-control study in Chinese Han population. J Epidemiol. 2015;25:387–391. doi:10.2188/jea.JE20140194.
   PubMed Web of Science ®Google Scholar
• Awan FM, Naz A, Obaid A, Ali A, Ahmad J, Anjum S, Janjua HA. Identification of circulating biomarker candidates for hepatocellular carcinoma (HCC): an integrated prioritization approach. Plos One. 2015;10:e0138913. doi:10.1371/journal.pone.0138913.
   PubMed Web of Science ®Google Scholar
• Bakiri L, Wagner EF. Mouse models for liver cancer. Mol Oncol. 2013;7:206–223. doi:10.1016/j.molonc.2013.01.005.
   PubMed Web of Science ®Google Scholar
• Rakhshandehroo M, Stienstra R, de Wit NJ, Bragt MC, Haluzik M, Mensink RP, Muller M, Kersten S. Plasma mannose-binding lectin is stimulated by PPARalpha in humans. Am J Physiol Endocrinol Metab. 2012;302:E595–602. doi:10.1152/ajpendo.00299.2011.
   PubMed Web of Science ®Google Scholar
• Sastry R, Wang JS, Brown DC, Ezekowitz RA, Tauber AI, Sastry KN. Characterization of murine mannose-binding protein genes Mbl1 and Mbl2 reveals features common to other collectin genes. Mamm genome. 1995;6:103–110.
   PubMed Web of Science ®Google Scholar
• Wan SS, Kuo N, Kryczek I, Zou WP, Welling TH. Myeloid cells in hepatocellular carcinoma. Hepatology. 2015;62:1304–1312. doi:10.1002/hep.27867.
   PubMed Web of Science ®Google Scholar
• Xu YP, Zhao WX, Xu JF, Li J, Hong ZF, Yin ZY, Wang XM. Activated hepatic stellate cells promote liver cancer by induction of myeloid-derived suppressor cells through cyclooxygenase-2. Oncotarget. 2016;7:8866–8878. doi:10.18632/oncotarget.6839.
   PubMedGoogle Scholar
• Zhao Y, Wang YQ, Wang Q, Liu ZR, Liu QF, Deng X. Hepatic stellate cells produce vascular endothelial growth factor via phospho-p44/42 mitogen-activated protein kinase/cyclooxygenase-2 pathway. Mol Cell Biochem. 2012;359:217–223. doi:10.1007/s11010-011-1016-x.
   PubMed Web of Science ®Google Scholar
• Choteau L, Parny M, Francois N, Bertin B, Fumery M, Dubuquoy L, Takahashi K, Colombel JF, Jouault T, Poulain D, et al. Role of mannose-binding lectin in intestinal homeostasis and fungal elimination. Mucosal Immunol. 2016;9:767–776. doi:10.1038/mi.2015.100.
   PubMed Web of Science ®Google Scholar
• Muto S, Takada T, Matsumoto K. Biological activities of human mannose-binding lectin bound to two different ligand sugar structures, Lewis A and Lewis B antigens and high-mannose type oligosaccharides. Biochim Biophys Acta. 2001;1527:39–46.
   PubMed Web of Science ®Google Scholar
• Ma Y, Uemura K, Oka S, Kozutsumi Y, Kawasaki N, Kawasaki T. Antitumor activity of mannan-binding protein in vivo as revealed by a virus expression system: mannan-binding proteindependent cell-mediated cytotoxicity. Proc Natl Acad Sci U S A. 1999;96:371–375.
   PubMed Web of Science ®Google Scholar
• Bouwman LH, Roos A, Terpstra OT, De Knijff P, Van Hoek B, Verspaget HW, Berger SP, Daha MR, Frolich M, Van Der Slik AR, et al. Mannose binding lectin gene polymorphisms confer a major risk for severe infections after liver transplantation. Gastroenterology. 2005;129:408–414. doi:10.1016/j.gastro.2005.06.049.
   PubMed Web of Science ®Google Scholar
• Ostrand-Rosenberg S, Fenselau C. Myeloid-derived suppressor cells: immune-suppressive cells that impair antitumor immunity and are sculpted by their environment. J Immunol. 2018;200:422–431. doi:10.4049/jimmunol.1701019.
   PubMed Web of Science ®Google Scholar
• Weber-Steffens D, Hunold K, Kurschner J, Martinez SG, Elumalai P, Schmidt D, Trevani A, Runza VL, Mannel DN. Immature mouse granulocytic myeloid cells are characterized by production of ficolin-B. Mol Immunol. 2013;56:488–496. doi:10.1016/j.molimm.2013.06.015.
   PubMed Web of Science ®Google Scholar
• Hernandez-Gea V, Toffanin S, Friedman SL, Llovet JM. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology. 2013;144:512–527. doi:10.1053/j.gastro.2013.01.002.
   PubMed Web of Science ®Google Scholar
• Eggert T, Greten TF. Tumor regulation of the tissue environment in the liver. Pharmacol Therapeut. 2017;173:47–57. doi:10.1016/j.pharmthera.2017.02.005.
   PubMed Web of Science ®Google Scholar
• Chou HS, Hsieh CC, Yang HR, Wang LF, Arakawa Y, Brown K, Wu QY, Lin F, Peters M, Fung JJ, et al. Hepatic stellate cells regulate immune response by way of induction of myeloid suppressor cells in mice. Hepatology. 2011;53:1007–1019. doi:10.1002/hep.24162.
   PubMed Web of Science ®Google Scholar
• Thompson AI, Conroy KP, Henderson NC. Hepatic stellate cells: central modulators of hepatic carcinogenesis. Bmc Gastroenterol. 2015;15:63. doi: 10.1186/s12876-015-0291-5.
   Web of Science ®Google Scholar
• Obermajer N, Kalinski P. Key role of the positive feedback between PGE(2) and COX2 in the biology of myeloid-derived suppressor cells. Oncoimmunology. 2012;1:762–764. doi:10.4161/onci.19681.
   PubMed Web of Science ®Google Scholar
• Loo TM, Kamachi F, Watanabe Y, Yoshimoto S, Kanda H, Arai Y, Nakajima-Takagi Y, Iwama A, Koga T, Sugimoto Y, et al. Gut microbiota promotes obesity-associated liver cancer through PGE2-mediated suppression of antitumor immunity. Cancer Discov. 2017;7:522–538. doi:10.1158/2159-8290.CD-16-0932.
   PubMed Web of Science ®Google Scholar
• Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastro Hepat. 2017;14:397–411. doi:10.1038/nrgastro.2017.38.
   PubMed Web of Science ®Google Scholar
• Qin YN, Zhong YG, Yang GL, Ma TR, Jia LY, Huang C, Li Z. Profiling of concanavalin A-binding glycoproteins in human hepatic stellate cells activated with transforming growth factor-beta 1. Molecules. 2014;19:19845–19867. doi:10.3390/molecules191219845.
   PubMed Web of Science ®Google Scholar
• Xu RN, Lin F, He J, Jin L, Zhang JY, Fu JL, Liu HH, Wang SY, Zhang Z, Wang FS. Complement 5a stimulates hepatic stellate cells in vitro, and is increased in the plasma of patients with chronic hepatitis B. Immunology. 2013;138:228–234. doi:10.1111/imm.12024.
   PubMed Web of Science ®Google Scholar
• Cheng CT, Yu S, Kong R, Yuan QG, Ma YF, Yang WB, Cao G, Xie LY. CTRP3 attenuates hepatic stellate cell activation through transforming growth factor-beta/Smad signaling pathway. Biomed Pharmacother. 2017;89:1387–1391. doi:10.1016/j.biopha.2017.03.021.
   PubMed Web of Science ®Google Scholar
• Saeed A, Baloch K, Brown RJP, Wallis R, Chen L, Dexter L, McClure CP, Shakesheff K, Thomson BJ. Mannan binding lectin-associated serine protease 1 is induced by hepatitis C virus infection and activates human hepatic stellate cells. Clin Exp Immunol. 2013;174:265–273. doi:10.1111/cei.12174.
   PubMed Web of Science ®Google Scholar
• Yoon JH, Kim KM, Kim W, Lee HS. Bile acid-mediated induction of cyclooxygenase-2 and Mcl-1 in hepatic stellate cells. Liver Int. 2006;26:30–31.
   Web of Science ®Google Scholar
• Ochoa-Callejero L, Perez-Martinez L, Rubio-Mediavilla S, Oteo JA, Martinez A, Blanco JR. Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse model. Plos One. 2013;8:e53992. doi:10.1371/journal.pone.0053992.
   PubMed Web of Science ®Google Scholar
• Nakhaei-Rad S, Nakhaeizadeh H, Gotze S, Kordes C, Sawitza I, Hoffmann MJ, Franke M, Schulz WA, Scheller J, Piekorz RP, et al. The role of embryonic stem cell-expressed RAS (ERAS) in the maintenance of quiescent hepatic stellate cells. J Biol Chem. 2016;291:8399–8413. doi:10.1074/jbc.M115.700088.
   PubMed Web of Science ®Google Scholar
• Guo L, Zhang P, Chen ZM, Xia HJ, Li SM, Zhang YQ, Kobberup S, Zou WP, Lin JD. Hepatic neuregulin 4 signaling defines an endocrine checkpoint for steatosis-to-NASH progression. J Clin Invest. 2017;127:4449–4461. doi:10.1172/JCI96324.
   PubMed Web of Science ®Google Scholar
• Dowd NP, Scully M, Adderley SR, Cunningham AJ, Fitzgerald DJ. Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J Clin Invest. 2001;108:585–590. doi:10.1172/JCI11334.
   PubMed Web of Science ®Google Scholar